Los puntos clave no están disponibles para este artículo en este momento.
The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity.
Conroy et al. (Wed,) studied this question.